Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 1,928	$ 624	$ 4,204	$ 1,630
In-process research and development	0	0	0	30,117
General and administrative	2,075	2,392	7,259	6,080
Restructuring costs (Note 10)	410	0	410	0
Total operating expenses	4,413	3,016	11,873	37,827
Loss from operations	(4,413)	(3,016)	(11,873)	(37,827)
Other income (expense):
Gain on forgiveness of PPP loan	0	0	0	279
Loss on issuance of secured debt	0	0	0	(686)
Gain on change in fair value of warrant liability	385	12,764	2,403	17,939
Gain on change in fair value of share liability	0	18	0	91
Interest expense	(4)	(26)	(10)	(2,393)
Other income	41	20	50	36
Loss on issuance of LBS Series 1 Preferred Stock	0	0	0	(1,881)
Loss on issuance of warrants	0	(1,673)	(1,110)	(3,247)
Total other income (expense)	422	11,103	1,333	10,138
Net (loss) income	$ (3,991)	$ 8,087	$ (10,540)	$ (27,689)
(Loss) income per common share:
Basic net (loss) income per common share	$ (0.08)	$ 0.42	$ (0.37)	$ (3.50)
Diluted net (loss) income per common share	$ (0.08)	$ 0.42	$ (0.37)	$ (4.13)
Weighted average shares used in computing (loss) income per common share:
Weighted average shares used in calculating basic (loss) income per share	48,709,846	12,100,292	28,634,209	7,902,104
Weighted average shares used in calculating diluted (loss) income per share	48,709,846	12,106,771	28,634,209	7,952,998
Net (loss) income attributable to common shares - basic	$ (3,991)	$ 5,118	$ (10,540)	$ (27,689)
Net (loss) income attributable to common shares - diluted	$ (3,991)	$ 5,119	$ (10,540)	$ (32,808)